BioNexus Gene Lab is a molecular diagnostics company focused on the application of functional genomics. Co.'s focus is on developing and marketing non-invasive blood tests for early detection of diseases. Co.'s non-invasive blood tests analyze changes in ribonucleic acid to detect the risk potentiality of various diseases. These diseases include cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate and colon), bowel diseases (colitis and Crohn) and osteoarthritis. This blood based genomic biomarker approach is based on the scientific observation that circulating blood reflects, in a detectable way, what is occurring throughout the body. The BGLC YTD return is shown above.
The YTD Return on the BGLC YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether BGLC YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BGLC YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|